• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

    3/4/25 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email

    First three consumer products expected to launch in Q3 2025, providing near-term revenue growth

    Jupiter, Florida, March 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan.

    "As we explore new ways to translate our scientific discoveries into tangible health solutions, we see an immense opportunity in the longevity and healthspan market," said Christer Rosén, Chairman & CEO of Jupiter Neurosciences. "Aquanova has been an exceptional technology partner, and their expertise in formulation and execution will be instrumental in this venture. We believe that our pharmaceutical-driven approach and the strong clinical foundation behind JOTROL™ provide a unique advantage in delivering high-quality, effective products to consumers."

    Jupiter and Aquanova have collaborated for over eight years in the development of Jupiter's lead product, JOTROL™, a proprietary resveratrol-based formulation currently advancing toward a Phase IIa trial in Parkinson's Disease. Based on the extensive preclinical and clinical data supporting JOTROL™'s potential in central nervous system (CNS) disorders such as Alzheimer's and Parkinson's, the companies are now leveraging their combined expertise to expand into the rapidly growing longevity and healthspan market.

    The jointly developed products will focus on the concept of "Beauty from Within," emphasizing scientifically backed formulations designed to support longevity and overall health. The first three products are expected to launch in Q3 2025 through a Direct-to-Consumer (DTC) model, providing an immediate commercial pathway while Jupiter continues its clinical development efforts.

    "We are incredibly proud of our partnership with Jupiter and look forward to the work they are doing to bring life-changing solutions for rare and difficult-to-treat diseases to market in the medicinal sphere and for superior supplement products targeting longevity and healthspan," said Frank Behnam, CEO of Aquanova. "Resveratrol is a powerful ingredient but it suffers from bioavailability and absorption challenges. Our NovaSOL™ technology ensures that resveratrol safely reaches effective levels in the body, without GI-side effects, creating reliable health solutions in many indications."

    As part of this initiative, Jupiter plans to launch these products under a new wholly owned subsidiary, allowing existing shareholders to participate in the commercial success of the venture. This subsidiary is expected to generate revenue which will support Jupiter's ongoing pharmaceutical trials.

    "We frequently hear from individuals interested in accessing JOTROL™ immediately, particularly those with personal connections to neurodegenerative diseases," Rosén added. "Like many, I have seen the devastating impact of Alzheimer's and Parkinson's firsthand. This initiative not only represents a strategic business expansion but also a meaningful step in addressing a growing consumer demand for science-backed solutions in aging and healthspan."

    About Jupiter Neurosciences, Inc.

    Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website www.jupiterneurosciences.com.

    About JOTROL

    Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.

    Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease.

    About Aquanova & NovaSOL® Technology

    Aquanova NA Corp. is the U.S. daughter company of Aquanova AG, headquartered in Germany, a leading phyto-technology manufacturer dedicated to enhancing the bioavailability of natural compounds. Founded in 1995, Aquanova AG offers scientifically proven health ingredients to customers worldwide. Utilizing its patented NovaSOL® technology, the company delivers micellized ingredients with superior efficacy and speed of absorption. www.aquanovacorp.com/ www.aquanova.de

    FORWARD-LOOKING STATEMENTS

    Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

    Contact:

    Dave Gentry

    RedChip Companies, Inc.

    1-407-644-4256

    1-800-RED-CHIP (733-2447)

    [email protected]



    Primary Logo

    Get the next $JUNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

      PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

      6/30/25 3:15:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

      GLO targets the growing "beauty-from-within" market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration. Unmatched Scienc

      6/27/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

      Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Annika Sörenstam, the most accomplished female professional golfer in history, has joined the Company as the first official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line. Annika, who has amassed over 95 international tournament victories—including 72 LPGA titles and 10 major championships—will collaborate with the Company to champion Nugevia's science-backed formulations designed for performance, f

      6/23/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    SEC Filings

    See more

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      5/15/25 4:31:24 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Jupiter Neurosciences Inc.

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      4/21/25 12:38:15 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Jupiter Neurosciences Inc.

      10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      3/28/25 5:01:29 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care